Singapore’s Merlion Seeks Further Licensing Deals After Bolster By U.S. FDA Fast-Track Status
This article was originally published in PharmAsia News
Executive Summary
Singapore’s MerLion Pharmaceuticals received a shot in the arm for its intravenous and oral antibiotic finafloxacin following U.S. FDA designation as a Qualified Infectious Disease Product and for fast track development. The designation opens up exclusive marketing rights for as long as 10 years if the candidate successfully completes Phase III trials.
You may also be interested in...
FDA Antibiotics Incentives List Goes Beyond GAIN Act
The agency’s proposed rule on qualifying pathogens is longer than the initial legislative list, but industry still awaits regulations on the law’s exclusivity bonus, which are only achieved through a separate qualified disease product designation.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.